Bright Minds Biosciences Return on Equity (ROE) Growth & History (DRUG)
Bright Minds Biosciences's return on equity was −27.93% for fiscal 2025.
View full Bright Minds Biosciences company overviewBright Minds Biosciences annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-09-30 | −27.93% | +18.25 pp |
| 2024 | 2024-09-30 | −46.18% | +39.84 pp |
| 2023 | 2023-09-30 | −86.02% | +13.93 pp |
| 2022 | 2022-09-30 | −99.95% | −14.01 pp |
| 2021 | 2021-09-30 | −85.94% | — |
Bright Minds Biosciences quarterly return on equity
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q3 2026 | 2026-06-30 | −0.78% | +8.97 pp |
| Q2 2026 | 2026-03-31 | −5.26% | +4.37 pp |
| Q1 2026 | 2025-12-31 | −8.83% | — |
| Q4 2025 | 2025-09-30 | −6.10% | — |
| Q3 2025 | 2025-06-30 | −9.75% | — |
| Q2 2025 | 2025-03-31 | −9.63% | — |
Bright Minds Biosciences return on equity trends
Between the periods ended 2021-09-30 and 2025-09-30, Bright Minds Biosciences's return on equity increased from −85.94% to −27.93%, a change of +58.02 percentage points. The latest reported quarter, Q3 2026, shows −0.78%.
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Bright Minds Biosciences source filings ↗